THERAPY DOSSIER · th-05107e222908

Recombinant IL-36R ligands (IL-36alpha and IL-36gamma)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26783184 ↗2016Reported benefit

IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo.

MouseChemical/toxinIL-36R-deficient and Myd88-deficient miceapplied to established experimental intestinal wounds

Model: Acute dextran sodium sulfate colitis and experimental intestinal mucosal wounds

Defective IL-36R signalling increased susceptibility to dextran sodium sulfate colitis and impaired wound healing, while treating experimental intestinal wounds with IL-36R ligands significantly accelerated mucosal healing in vivo.

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…